Skip to main
RANI
RANI logo

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. is leading the development of innovative oral delivery technologies through its proprietary RaniPill platform, which has demonstrated impressive preclinical data suggesting effective drug administration alternatives to traditional injections. The company's focus on progressing its pipeline, particularly in the obesity treatment sector with the upcoming Phase 1c trials and potential Phase 2a trials for RT-114, highlights its strategic positioning in a lucrative multi-billion dollar market. Additionally, partnerships like the one with ProGen are expanding Rani's capabilities to advance multiple obesity programs, further strengthening its growth potential and competitive stance in the biotherapeutics landscape.

Bears say

Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to the competitive landscape and management issues. The presence of several companies developing long-acting injectable formulations poses a threat to the competitive advantage of Rani's oral RaniPill, potentially limiting market share and creating pricing pressures. Furthermore, the risks associated with clinical development, including negative Phase 2 data, approval uncertainties, management turnover, and potential delays in FDA approvals, may hinder progress and negatively impact Rani’s financial performance and stock viability.

RANI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 11 analysts, RANI has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.